Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Receivables (2020 - 2021)

Gain Therapeutics (GANX) has 2 years of Change in Receivables data on record, last reported at -$24429.0 in Q4 2021.

  • For Q4 2021, Change in Receivables fell 465.32% year-over-year to -$24429.0; the TTM value through Dec 2021 reached -$8264.0, down 4316.33%, while the annual FY2021 figure was -$8264.0, 4316.33% down from the prior year.
  • Change in Receivables reached -$24429.0 in Q4 2021 per GANX's latest filing, up from -$328453.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $513738.0 in Q1 2021 and bottomed at -$328453.0 in Q3 2021.